Gaucher's disease medical therapy: Difference between revisions
No edit summary |
|||
| Line 13: | Line 13: | ||
For type 1 and most type 3 patients, [[enzyme replacement treatment]] with mannose-terminated [[Recombinant DNA|recombinant]] glucocerebrosidase, 60 Units/kg, given [[intravenous]]ly every two weeks can dramatically decrease [[liver]] and [[spleen]] size, reduce skeletal abnormalities, and reverse other manifestations. This treatment is becoming the standard in treating Gaucher's. Due to the low incidence, this has become an [[orphan drug]] in many countries. | For type 1 and most type 3 patients, [[enzyme replacement treatment]] with mannose-terminated [[Recombinant DNA|recombinant]] glucocerebrosidase, 60 Units/kg, given [[intravenous]]ly every two weeks can dramatically decrease [[liver]] and [[spleen]] size, reduce skeletal abnormalities, and reverse other manifestations. This treatment is becoming the standard in treating Gaucher's. Due to the low incidence, this has become an [[orphan drug]] in many countries. | ||
===Supportive | ===Supportive Treatment=== | ||
Other treatment options include [[antibiotic]]s for [[infection]]s, [[antiepileptic]]s for seizures, bisphosphonates for bone lesions, and [[liver transplant]]s. Substrate reduction therapy may prove to be effective in stopping Type 2, as it can cross through the blood barrier into the brain. There is currently no effective treatment for the severe brain damage that may occur in patients with types 2 and 3 Gaucher disease. | Other treatment options include [[antibiotic]]s for [[infection]]s, [[antiepileptic]]s for seizures, bisphosphonates for bone lesions, and [[liver transplant]]s. Substrate reduction therapy may prove to be effective in stopping Type 2, as it can cross through the blood barrier into the brain. There is currently no effective treatment for the severe brain damage that may occur in patients with types 2 and 3 Gaucher disease. | ||
| Line 19: | Line 19: | ||
The currently existing treatment of Gaucher's disease, Cerezyme ([[imiglucerase]] for injection), costs up to $550,000 annually for a single patient and the treatment should be continued for life. This recombinant β-glucosidase is given intravenously. [[Miglustat]] is another drug approved for this disease in 2003. | The currently existing treatment of Gaucher's disease, Cerezyme ([[imiglucerase]] for injection), costs up to $550,000 annually for a single patient and the treatment should be continued for life. This recombinant β-glucosidase is given intravenously. [[Miglustat]] is another drug approved for this disease in 2003. | ||
===Bone marrow transplantation=== | |||
Successful [[bone marrow transplantation]] cures the non-neurological manifestations of the disease, because it introduces a [[monocyte]] population with active β-glucosidase. However, this procedure carries significant risk and is rarely performed in Gaucher patients. [[Blood transfusion]] may benefit some anemic patients. | |||
Latest revision as of 18:26, 31 August 2012
|
Gaucher's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Gaucher's disease medical therapy On the Web |
|
American Roentgen Ray Society Images of Gaucher's disease medical therapy |
|
Risk calculators and risk factors for Gaucher's disease medical therapy |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Medical Therapy
Enzyme replacement treatment
For type 1 and most type 3 patients, enzyme replacement treatment with mannose-terminated recombinant glucocerebrosidase, 60 Units/kg, given intravenously every two weeks can dramatically decrease liver and spleen size, reduce skeletal abnormalities, and reverse other manifestations. This treatment is becoming the standard in treating Gaucher's. Due to the low incidence, this has become an orphan drug in many countries.
Supportive Treatment
Other treatment options include antibiotics for infections, antiepileptics for seizures, bisphosphonates for bone lesions, and liver transplants. Substrate reduction therapy may prove to be effective in stopping Type 2, as it can cross through the blood barrier into the brain. There is currently no effective treatment for the severe brain damage that may occur in patients with types 2 and 3 Gaucher disease.
Gaucher's disease has recently become a target for more than one effort at pharmacological chaperoning since the crystal structure of glucocerebrosidase is known.
The currently existing treatment of Gaucher's disease, Cerezyme (imiglucerase for injection), costs up to $550,000 annually for a single patient and the treatment should be continued for life. This recombinant β-glucosidase is given intravenously. Miglustat is another drug approved for this disease in 2003.
Bone marrow transplantation
Successful bone marrow transplantation cures the non-neurological manifestations of the disease, because it introduces a monocyte population with active β-glucosidase. However, this procedure carries significant risk and is rarely performed in Gaucher patients. Blood transfusion may benefit some anemic patients.